Lataa...
Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis
The novel ATP synthase inhibitor bedaquiline recently received accelerated approval for treatment of multidrug-resistant tuberculosis and is currently being studied as a component of novel treatment-shortening regimens for drug-susceptible and multidrug-resistant tuberculosis. In a limited number of...
Tallennettuna:
| Julkaisussa: | Antimicrob Agents Chemother |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society for Microbiology
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4958187/ https://ncbi.nlm.nih.gov/pubmed/27185800 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00753-16 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|